Tenax Therapeutics (TENX) Stock Forecast, Price & News

Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

Is Tenax Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Tenax Therapeutics stock.
View analyst ratings for Tenax Therapeutics or view top-rated stocks.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 22,900 shares, a decline of 45.3% from the April 15th total of 41,900 shares. Based on an average daily volume of 39,900 shares, the short-interest ratio is presently 0.6 days.
View Tenax Therapeutics' Short Interest.

When is Tenax Therapeutics' next earnings date?

Tenax Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 23rd 2022.
View our earnings forecast for Tenax Therapeutics.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) released its quarterly earnings data on Tuesday, November, 16th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02.
View Tenax Therapeutics' earnings history.

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Shares of Tenax Therapeutics reverse split before market open on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for TENX?

1 brokerages have issued 1-year price objectives for Tenax Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Tenax Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 635.3% from the stock's current price.
View analysts' price targets for Tenax Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the following people:

• Mr. Christopher T. Giordano, CEO, Pres & Director (Age 47)
• Mr. Eliot M. Lurier CPA, Interim Chief Financial Officer (Age 64)
• Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
• Mr. Doug Randall, Exec. VP of Commercial & Bus. Operations
• Dr. Douglas Hay, Sr. VP of Regulatory Affairs
• Dr. Stuart Rich M.D., Chairman of Scientific Advisory Board, Chief Medical Officer & Director (Age 72)

Who are some of Tenax Therapeutics' key competitors?

Some companies that are related to Tenax Therapeutics include SCYNEXIS (SCYX), Adamis Pharmaceuticals (ADMP), InflaRx (IFRX), Lumos Pharma (LUMO), Lantern Pharma (LTRN), Ainos (AIMD), Akari Therapeutics (AKTX), Eyenovia (EYEN), DiaMedica Therapeutics (DMAC), Atreca (BCEL), Akebia Therapeutics (AKBA), Molecular Templates (MTEM), Oncolytics Biotech (ONCY), Bolt Biotherapeutics (BOLT) and Seelos Therapeutics (SEEL).
View all of TENX's competitors.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Tenax Therapeutics stock include Armistice Capital Master Fund and Armistice Capital, Llc.
View institutional ownership trends for Tenax Therapeutics.

How do I buy shares of Tenax Therapeutics?

Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $0.68.

How much money does Tenax Therapeutics make?

Tenax Therapeutics has a market capitalization of $17.14 million. The specialty pharmaceutical company earns $-32.47 million in net income (profit) each year or ($2.490010) on an earnings per share basis.

How many employees does Tenax Therapeutics have?

Tenax Therapeutics employs 8 workers across the globe.

When was Tenax Therapeutics founded?

Tenax Therapeutics was founded in 1967.

What is Tenax Therapeutics' official website?

The official website for Tenax Therapeutics is www.tenaxthera.com.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100, via email at [email protected], or via fax at 919-855-2133.